Am­gen takes next step with its Chi­na am­bi­tions, out-li­cens­ing drugs to Fo­s­un Phar­ma

In a bid to in­crease its mar­ket share in Chi­na, Am­gen has agreed to a part­ner­ship with a Shang­hai biotech — a col­lab­o­ra­tion and out-li­cens­ing agree­ment for two of its drugs.

Am­gen and Fo­s­un Phar­ma an­nounced a deal Mon­day in a bid to in­crease Am­gen’s pres­ence in the coun­try. The stat­ed goal so far is to com­mer­cial­ize Am­gen’s block­buster pso­ri­a­sis drug Ote­zla along­side Parsabiv, a drug for sec­ondary hy­per­parathy­roidism in adults with chron­ic kid­ney dis­ease and on a spe­cif­ic type of dial­y­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER